Single-Cell Transcriptomic Identification of Profibrotic Macrophage Drug Targets in Idiopathic Pulmonary Fibrosis: A Computational Repurposing Study

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This paper describes a computational drug repurposing study for idiopathic pulmonary fibrosis (IPF) using single-cell RNA sequencing data from GSE136831 (Adams et al. 2020, Nature Communications; 312,928 lung cells, 32 donors). A standardized scVI-based pipeline was applied to 19,775 high-quality IPF and control cells. Leiden clustering identified two macrophage-enriched clusters (Leiden 2 and 3; 11,122 cells, 56.2% of dataset) characterized by co-expression of C1QA/B/C, MARCO, APOE, SPP1, CCL18, and TYROBP. Wilcoxon differential expression yielded 353 upregulated macrophage genes. LINCS L1000 Enrichr query and ChEMBL bioactivity scoring (Score = N_targets x 10 + max_pChEMBL) identified 12 NOVEL_ALL drug repurposing candidates. Top candidates are naloxone (Score 219.66, opioid receptor/macrophage polarization axis), oseltamivir (Score 210.22, neuraminidase/Siglec-mediated macrophage activation), rifamycin (Score 148.07, PXR nuclear receptor anti-fibrotic signaling), and camostat (Score 138.80, TMPRSS2/PAR serine protease pathway). This work is a companion to US Provisional Patent Application 64/020,036. Pipeline code: github.com/glenritschel/ipf-scrna.

Fields of Study & Subjects

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Computational Drug Discovery Methods Systemic Sclerosis and Related Diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
28 March 2026
Language
EN
Document type
Preprint